Theory Paper IIDrNB Cardiology – Theory Notes
MANAGEMENT OF MECHANICAL PROSTHETIC HEART VALVE (PHV) THROMBOSIS
ICORE CONCEPTS AND CLINICAL URGENCY
- The Clinical Emergency: Mechanical PHV thrombosis is a life-threatening complication, more common in the Mitral and Tricuspid positions due to lower flow velocities.
- The Pathophysiology: It results from inadequate anticoagulation, leading to the formation of an obstructive clot that restricts leaflet motion, causing acute heart failure or systemic embolism.
- The Critical Distinction: One must differentiate Thrombus (acute, soft, associated with sub-therapeutic INR) from Pannus (chronic, fibrous ingrowth, slow progression, independent of INR).
IIDIAGNOSTIC WORKUP FOR MANAGEMENT
- Cine-Fluoroscopy: The gold standard for assessing leaflet mobility. A restricted “opening or closing angle” confirms obstruction.
- Transthoracic (TTE) and Transesophageal Echo (TEE):
- Essential to measure the Mean Gradient. An increase in gradient (e.g., doubling from baseline) is highly suggestive.
- TEE is mandatory to quantify the size of the thrombus (measured in square cm or mm).
- Multidetector CT (MDCT): Highly accurate in differentiating low-attenuation thrombus from high-attenuation pannus.
IIIMANAGEMENT RECOMMENDATIONS (2021 ESC/EACTS & 2020 ACC/AHA)
The choice of therapy depends on the Clinical Stability of the patient and the Size/Location of the thrombus.
AObstructive Thrombus (Critical Stenosis)
- Emergency Surgery (ESC Class I): Preferred for critically ill patients (NYHA Class 3 or 4) without serious comorbidity who are good surgical candidates. (2020 ACC/AHA gives a Class I recommendation to either urgent low-dose slow-infusion fibrinolysis or emergency surgery for symptomatic obstructive left-sided thrombosis.)
- Fibrinolysis (ESC Class IIa): Considered if:
- Surgery is high-risk or unavailable.
- The thrombus is on the Right Side (Tricuspid).
- The patient is in extremis (too unstable for the OR).
BNon-Obstructive Thrombus (Incidental Finding)
- Small Thrombus (Less than 10 mm or 0.8 square cm): Managed with optimized Heparin/Warfarin therapy.
- Large Thrombus (Greater than 10 mm):
- If associated with embolism: Surgery or Fibrinolysis is indicated.
- If asymptomatic: Intense anticoagulation is tried first; if the thrombus does not regress, surgery is indicated to prevent future embolism.
IVTHE EVIDENCE BASE: LANDMARK TRIALS
- The TROIA Study (Özkan et al., 2013): A large multicentre observational registry of TEE-guided fibrinolysis. Low-Dose, Slow-Infusion Tissue Plasminogen Activator (tPA) (25 mg over 6 hours, repeated if needed) was associated with fewer complications (embolism and bleeding) than higher-dose rapid regimens while maintaining high success rates; the ultra-slow 25-hour infusion was evaluated in later studies by the same group.
- PROACT and PROACT Xa Trials: PROACT showed that a lower INR target (1.5 to 2.0) after 3 months was non-inferior for thromboembolism with less bleeding in the On-X aortic valve specifically; PROACT Xa (apixaban versus warfarin in On-X aortic valves) was stopped early for excess thromboembolic events with apixaban, confirming that vitamin K antagonists remain mandatory for mechanical valves.
- The “Slow Infusion” Evidence: Observational series suggest that slower infusion regimens are associated with lower embolic and bleeding complications in stable patients.
VFIBRINOLYSIS PROTOCOL (THE DISTINCTION DATA)
- Agent: Recombinant tPA (Alteplase).
- Dosage: 25 mg slow infusion over 6 to 25 hours.
- Monitoring: Continuous TTE and Fluoroscopy to watch for leaflet “opening.”
- Contraindications: Large Left Atrial Thrombus, recent stroke, or active internal bleeding.
VIPRACTICAL CONSIDERATIONS IN THE INDIAN CLINICAL CONTEXT
- The “Sub-Therapeutic” Reality: Many Indian cases are related to inconsistent drug supply or poor INR monitoring in rural areas.
- The Fibrinolysis Preference: Given the limited access to cardiac surgical units in many parts of India, Low-Dose, Slow-Infusion Fibrinolysis is often the practical first-line strategy for stable patients in non-surgical centers.
- The Streptokinase Alternative: While tPA is preferred, Streptokinase (2.5 Lakh units bolus followed by 1 Lakh units per hour) is still a valid, cost-effective alternative in Indian settings if tPA is unaffordable.
- Post-Recovery Plan: Structured anticoagulation education before discharge is essential, together with Home INR monitoring if feasible to prevent recurrence.
Key references
- Vahanian A, Beyersdorf F, Praz F, et al.: 2021 ESC/EACTS Guidelines for the management of valvular heart disease, European Heart Journal, 2022.
- Otto CM, Nishimura RA, Bonow RO, et al.: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease, Circulation, 2021.
- Özkan M, Gündüz S, Biteker M, et al.: Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial, JACC: Cardiovascular Imaging, 2013.
meritmedscript.comDr. Sidhartha Mullapudi
